The recombinant zoster vaccine is effective in preventing herpes zoster in adults aged 50 years or older with rheumatoid ...
Curevo, a Seattle-based biotech startup developing a vaccine against shingles, raised $110 million in a Series B round.
The shingles vaccine is recommended for healthy adults age 50 or older, and also for anyone age 19 years or older who has a ...
Moncef Slaoui, who ran the Operation Warp Speed Covid vaccine effort, is becoming chair of Curevo, a company developing a new ...
Amezosvatein has shown excellent immunogenicity and improved tolerability in Phase 2 study -- Medicxi leads round, joined by ...
Pharmaceutical Technology on MSN3d
Curevo procures $110m and former-GSK exec for shingles vaccine candidateCurevo has set its sights on competing with GSK’s shingles vaccine dominance by securing $110m and securing a former ...
Most pediatric transplant recipients who received live-attenuated viral vaccines after transplant developed protective ...
Patients who have a date of birth from September 2, 1943 and August 31, 1953 will have previously been called for vaccination ...
Curevo has set its sights on competing with GSK’s shingles vaccine dominance by securing $110m and securing a former executive from the UK big pharma to advance its candidate amezosvatein.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results